Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa

Dissertation (MSc (Medical Virology))--University of Pretoria, 2021.

Saved in:
Bibliographic Details
Other Authors: Lukhwareni, Azwidowi
Format: Thesis
Language:English
Published: University of Pretoria 2021
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613460583415808
access_status_str Open Access
author2 Lukhwareni, Azwidowi
author_browse Lukhwareni, Azwidowi
author_facet Lukhwareni, Azwidowi
collection Thesis
dc_rights_str_mv © 2019 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
description Dissertation (MSc (Medical Virology))--University of Pretoria, 2021.
format Thesis
id oai:repository.up.ac.za:2263/79141
institution University of Pretoria (South Africa)
language English
last_indexed 2026-06-10T12:36:30.275Z
license_str Other — see source repository
provenance_str_mv Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher University of Pretoria
publisherStr University of Pretoria
record_format dspace
source_str UPSpace — University of Pretoria Institutional Repository
spelling oai:repository.up.ac.za:2263/79141 Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa Lukhwareni, Azwidowi u15187030@tuks.co.za Rossouw, Theresa M. Smit, Odette Medical Virology UCTD Human immunodeficiency virus (HIV) Prevention of mother-to-child transmission (PMTCT) Early infant diagnosis (EID) HIV drug resistance (HIVDR) Antiretroviral therapy (ART) Roche COBAS®AmpliPrep (CAP)/COBAS®TaqMan® (CTM) Roche cobas® 6800/8800 System Dried blood samples (DBS) Cycle threshold (Ct) Relative fluorescent intensity (RFI) Health sciences theses SDG-03 SDG-03: Good health and well-being Health sciences theses SDG-05 SDG-05: Gender equality Health sciences theses SDG-09 SDG-09: Industry, innovation and infrastructure Dissertation (MSc (Medical Virology))--University of Pretoria, 2021. Despite the high prevalence of the human immunodeficiency virus (HIV) in South African women of reproductive age, the South African (SA) Prevention of Mother-to-Child Transmission (PMTCT) programme has significantly reduced the incidence of new HIV infections in infants from >20% in 2004 to <2% and overall MTCT approximately >5%. The PMTCT programme, however, faces challenges in terms of early infant diagnosis (EID) because of HIV polymerase chain reaction (PCR) indeterminate results as well as HIV drug resistance (HIVDR) secondary to antiretroviral therapy (ART) exposure of mothers and infants. The National Health and Laboratory Services (NHLS) uses the Roche COBAS®AmpliPrep (CAP)/COBAS®TaqMan® (CTM) HIV-1 Qualitative Test (Roche Molecular Systems, Pleasanton, CA) (CAP/CTM) platform as part of EID. Recently, the Roche cobas® 6800/8800 System has been introduced to test HIV viral load and HIV DNA PCR for EID. The platform is already processing samples for HIV viral load; however, verification for HIV DNA PCR for EID with dried blood samples (DBS) is needed, especially for CAP/CTM HIV PCR indeterminate results (Cycle threshold [Ct]>33 with any relative fluorescent intensity [RFI] value or Ct≤33 and RFI <5 on the CAP/CTM, Ct>38 on the Roche cobas® 6800/8800 System). In addition, HIVDR in newly diagnosed infants significantly limits treatment options. Therefore, the current study verified the Roche cobas® 6800/8800 System against the CAP/CTM system for the detection of HIV in EID and determined the HIVDR prevalence and profiles in infants <6 months, and how this affects current SA PMTCT and EID guidelines. The study comprised 642 DBS samples (235 HIV PCR positive, 193 HIV PCR negative and 214 HIV PCR indeterminate) previously tested on the CAP/CTM assay. Overall, 99.6% (234/235) CAP/CTM HIV PCR positive samples remained positive, while 99.5% (192/193) HIV PCR negative samples remained negative with the Roche cobas® 6800/8800 System. The HIV PCR indeterminate results as detected by the CAP/CTM decreased from 100% (214/214) to 8.4% (18/214) with the Roche cobas® 6800/8800 System. The Roche cobas® 6800/8800 System had a specificity of 99.5% and a sensitivity of 99.6%, but this decreased to 96.3% and 90.8% when HIV PCR indeterminate results were included. The kappa value increased from 0.5, which signifies moderate agreement, to 0.9, which is excellent agreement, when RFI from the CAP/CTM was excluded for result determination. The overall agreement between the two assays, taking only cycle threshold values into account, was 93.8%. As for HIVDR, mutations were detected in 42.9% (24/56) of infants <6 months. The most common non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation causing high-level resistance was K103N (21.4% [12/56]), followed by Y181C and the NRTI mutation, M184V, both in 8.9% (5/56) of infants. Also, major protease inhibitor (PI) mutations, M46L and V82A were detected in one case each (1.8%). In conclusion, the performance of the Roche cobas®6800/8800 System was comparable to the CAP/CTM; however, it detected fewer HIV PCR indeterminate results, thus potentially offering conclusive results in a larger proportion of infants. The detection of high levels of the NNRTI mutation, K103N, emphasises the need for constant surveillance since nevirapine is included as part of the SA PMTCT guidelines and the World Health Organization recommends that NNRTIs should be phased-out of as part of PMTCT once the resistance prevalence exceeds 10%. National Health Laboratory Services Trust and RDP UP em2025 Medical Virology MSc (Medical Virology) Restricted SDG-03: Good health and well-being SDG-05: Gender equality SDG-09: Industry, innovation and infrastructure 2021-03-30T08:38:00Z 2021-03-30T08:38:00Z 2021-04-16 2021-01 Dissertation Smit, O 2021, Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa, MSc (Medical Virology) Dissertation, University of Pretoria, Pretoria, viewed yymmdd <http://hdl.handle.net/2263/79141> A2021 http://hdl.handle.net/2263/79141 en © 2019 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf University of Pretoria
spellingShingle Medical Virology
UCTD
Human immunodeficiency virus (HIV)
Prevention of mother-to-child transmission (PMTCT)
Early infant diagnosis (EID)
HIV drug resistance (HIVDR)
Antiretroviral therapy (ART)
Roche COBAS®AmpliPrep (CAP)/COBAS®TaqMan® (CTM)
Roche cobas® 6800/8800 System
Dried blood samples (DBS)
Cycle threshold (Ct)
Relative fluorescent intensity (RFI)
Health sciences theses SDG-03
SDG-03: Good health and well-being
Health sciences theses SDG-05
SDG-05: Gender equality
Health sciences theses SDG-09
SDG-09: Industry, innovation and infrastructure
Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa
title Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa
title_full Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa
title_fullStr Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa
title_full_unstemmed Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa
title_short Early infant HIV diagnosis and characterization of HIV drug resistance in Gauteng, South Africa
title_sort early infant hiv diagnosis and characterization of hiv drug resistance in gauteng south africa
topic Medical Virology
UCTD
Human immunodeficiency virus (HIV)
Prevention of mother-to-child transmission (PMTCT)
Early infant diagnosis (EID)
HIV drug resistance (HIVDR)
Antiretroviral therapy (ART)
Roche COBAS®AmpliPrep (CAP)/COBAS®TaqMan® (CTM)
Roche cobas® 6800/8800 System
Dried blood samples (DBS)
Cycle threshold (Ct)
Relative fluorescent intensity (RFI)
Health sciences theses SDG-03
SDG-03: Good health and well-being
Health sciences theses SDG-05
SDG-05: Gender equality
Health sciences theses SDG-09
SDG-09: Industry, innovation and infrastructure
url http://hdl.handle.net/2263/79141